

1 **Title: Cost & Cost-Effectiveness of Implementing SD Biosensor Antigen Detecting SARs-CoV-2**  
2 **Rapid Diagnostic Tests in Kenya**

3 Authors:

4 Brian Arwah<sup>1</sup>, Samuel Mbugua<sup>2</sup>, Jane Ngure<sup>2</sup>, Mark Makau<sup>2</sup>, Peter Mwaura<sup>2</sup>, David Kamau<sup>2</sup>, Desire Aime  
5 Nshimirimana<sup>3</sup>, Edwine Barasa<sup>1,4,5</sup>, Jesse Gitaka<sup>2</sup>

6 1. Health Economics Research Unit, KEMRI – Wellcome Trust Research Programme

7 2. Directorate of Grant and Development, Mount Kenya University, Thika Kenya

8 3. Kenya Methodist University

9 4. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of  
10 Oxford, Oxford, UK

11 5. Institute of Healthcare Management, Strathmore University Business School, Nairobi, Kenya

12 Correspondence to: Brian Arwah; [barwah@kemri-wellcome.org](mailto:barwah@kemri-wellcome.org)

## 13 Abstract

14 The COVID-19 pandemic has created a need to rapidly scale-up testing services. In Kenya, services for  
15 SARS-CoV-2 nucleic acid amplifying test (NAAT) have often been unavailable or delayed, precluding the  
16 clinical utility of the results. The introduction of antigen-detecting rapid diagnostic tests (Ag-RDT) has had  
17 the potential to fill at least a portion of the ‘testing gap’. We, therefore, evaluated the cost-effectiveness  
18 of implementing SD Biosensor Antigen Detecting SARS-CoV-2 Rapid Diagnostic Tests in Kenya.

19 We conducted a cost and cost-effectiveness of implementing SD biosensor antigen-detecting SARS-CoV-  
20 2 rapid diagnostic test using a decision tree model following the Consolidated Health Economic Evaluation  
21 Standards (CHEERS) guidelines under two scenarios. In the first scenario, we compared the use of Ag-RDT  
22 as a first-line diagnostic followed by using NAAT assay, to the use of NAAT only. In the second scenario,  
23 we compared the use of Ag-RDT to clinical judgement. We used a societal perspective and a time horizon  
24 of patient care episodes. Cost and outcomes data were obtained from primary and secondary data. We  
25 used one-way and probabilistic sensitivity analysis to assess the robustness of the results.

26 At the point of care, Ag-RDT use for case management in settings with access to delayed confirmatory  
27 NAAT testing, the use of Ag-RDT was cost-effective (ICER = US\$ 964.63 per DALY averted) when compared  
28 to Kenya’s cost-effectiveness threshold (US\$ 1003.4). In a scenario with no access to NAAT, comparing the  
29 Ag-RDT diagnostic strategy with the no-test approach, the results showed that Ag-RDT was a cost-saving  
30 and optimal strategy (ICER = US\$ 1490.33 per DALY averted).

31 At a higher prevalence level and resource-limited setting such as Kenya, implementing Ag-RDT to  
32 complement NAAT testing will be a cost-effective strategy in a scenario with delayed access to NAAT and  
33 a cost-saving strategy in a scenario with no access to NAAT assay.

34

35 **Keywords:** Cost-effectiveness, SARS-CoV-2, Ag-RDT, NAAT assay, ICER

## 36 Introduction

37 The COVID-19 pandemic has created a need to rapidly scale-up testing services and provide diagnoses to  
38 implement test-trace-isolate strategies, essential to treat and care for patients and to control the spread  
39 of the virus. Hundreds of diagnostic products are now available on the market, targeting the detection of  
40 viral RNA, viral antigens, and host antibodies against SARS-CoV-2.

41 Services for SARS-CoV-2 Nucleic acid amplification testing (NAAT) assays have often been unavailable or  
42 backlogged for several days to weeks, precluding the clinical utility of the results. NAAT, a reverse  
43 transcription polymerase chain reaction (PCR) molecular testing of respiratory tract samples, is the  
44 recommended method for confirmation of COVID-19. In low and middle-income countries, however, the  
45 availability and health impact of PCR testing can be jeopardized by lack of testing capacity, insufficient  
46 trained personnel, shortages of reagents, long turnaround times (TAT), and high costs [1]. Lateral flow  
47 antigen-detecting rapid diagnostic tests (Ag-RDTs), which are easy to perform and provide results within  
48 15-30 minutes, have recently been commercialized and have the potential to fill at least a portion of the  
49 'testing gap'. Under certain conditions, Ag-RDTs that meet minimum performance requirements are  
50 recommended, and some have WHO Emergency Use Listing authorization [2]. These simple-to-use tests  
51 offer the possibility of rapid case detection, especially of the most infectious patients in the first week of  
52 illness, at or near the point of care.

53 WHO released an interim guidance on the use of Ag-RDTs for SARS-CoV-2, and the use of Ag-RDTs is  
54 recommended when PCR is either unavailable or long TAT of PCR which delays its clinical utility. This is  
55 particularly the case in less privileged countries in Africa, especially in Sub-Saharan Africa [3].

56 National norms and policies are being adopted in Kenya and many countries to allow and encourage  
57 targeted use of these Ag-RDTs. The decision to fully implement rapid diagnostic kits for detecting SARS-  
58 CoV-2 in Kenya relies on the field performance, feasibility, acceptability, and cost-effectiveness of the RDT  
59 compared to other diagnostic methods in the different settings which involve point-of-care diagnosis of  
60 COVID-19.

61 A published study of Ricks et al. analyzed the health system cost and health impact of using RDTs among  
62 hospitalized and symptomatic patients with SARS-COV2, and confirmed that despite the low sensitivity of  
63 RDTs compared with RT-PCR, the Ag-RDTs have the potential to be more impactful with less cost per death  
64 and more infections averted [4]. Studies have focused on effectiveness of testing kits and leaving behind  
65 cost effectiveness research however, a specific approach to assess cost-effectiveness of health

66 interventions suggested by the commission on macroeconomics and Health (WHO,2001) is that  
67 interventions costing less than the per capita gross domestic product (GDP) in Low and Middle-Income  
68 Countries (LMICs) are “very cost-effective”, and those costing less than triple the per capita GDP are “cost-  
69 effective [5]. This, therefore, raises one question, under which scenario in the point-of-care diagnosis is  
70 RDT cost-effective? The objective of this study was to evaluate the cost effectiveness of SD Biosensor  
71 Antigen Detecting SARs-CoV-2 Rapid Diagnostic Tests in Kenya.

## 72 **Methods**

### 73 **Study Design**

74 We developed a decision tree model in TreeAge Pro Healthcare 2021 to evaluate the cost-effectiveness  
75 of implementing SD biosensor antigen detecting SARS-CoV-2 rapid diagnostic tests in Kenya from a  
76 societal perspective. We modeled the costs and outcomes for diagnosing and treating COVID-19 patients  
77 in line with WHO interim guidance on antigen detection for COVID-19 using rapid immunoassays [6] and  
78 the Kenya ministry of health COVID-19 case management guidelines [7].

79 The diagnostic and treatment pathway followed the cases where symptomatic patients with suspected  
80 COVID-19 and asymptomatic contacts of COVID-19 cases attend health facilities with i) no access to NAAT  
81 for diagnosis or ii) limited access with prolonged turnaround times precluding clinical utility of results.

### 82 **Evaluation Scenarios**

83 We assessed two scenarios:

#### 84 **Point of care Ag-RDT use for case management in settings with access to delayed confirmatory NAAT** 85 **testing scenario.**

86 The scenario represented a health facility that sends samples to an external lab for NAAT, often with  
87 delayed result reporting. In this situation, Ag-RDT would be the first-line test to allow for case detection  
88 and rapid implementation of isolation procedures amongst positives and prioritization of negatives for  
89 confirmatory testing by NAAT at a designated laboratory facility. We compare the scenario with patients  
90 subjected to NAAT test, which is associated with a long turn-around time but obviates the need for  
91 confirmatory testing of negatives or a case whereby there is no testing. The diagnosis only relies on the  
92 clinical presentation of COVID-19 symptoms as per WHO case definitions [8].

93

94 **Point of care Ag-RDT use for case management in settings with no access to confirmatory NAAT testing**  
95 **scenario.**

96 The scenario differs from the first one since the target location involves a health facility with no access to  
97 NAAT and no secure means for the safe and timely transport of samples to centralized facilities. The  
98 scenario presents a case whereby Ag-RDT is the only feasible tool to aid in the diagnosis or a choice of not  
99 conducting a COVID-19 test.

100 **Sampling and sample size**

101 We selected two counties in Kenya, Kiambu, and Nairobi counties, to assess the field performance,  
102 feasibility, acceptability, and impact of SD biosensor antigen detecting SARS-CoV-2 rapid diagnostic tests.  
103 The two counties were chosen since they had the highest prevalence of COVID-19 in Kenya (average at  
104 >3% over the past three months), they also had different levels of government-owned facilities, and they  
105 had communities that were at high risk of outbreaks. We sampled four facilities that captured the diversity  
106 of access for COVID-19 testing and drew a sample size of 18 patients to capture the patient cost  
107 perspective. The patients' sample size was selected to achieve balance in the facilities chosen and we  
108 settled on the 18 patients after reaching saturation.

109 Using the previously proposed method by Buderer 1996, the initial sample size needed for the COVID-19  
110 RDT assumed the following expected values: test sensitivity of 80%, confidence interval of 5%, and COVID-  
111 19 prevalence of 10% to yield an estimated sample size of 2459 participants. Due to low turnout in daily  
112 tests conducted, a sample size of 506 participants was included in the study, which was still a  
113 representation of the targeted population assuming a test sensitivity of 85%, confidence interval of 5%, a  
114 width of 10%, and COVID-19 prevalence of 5% to 10%. To achieve the necessary accuracy on performance  
115 estimates, we determine data for negative cases (by NAAT) using a value of 50% for each estimate.

116 **Data Collection**

117 We used primary and secondary data to determine the cost components of diagnosis and case  
118 management of suspected Covid-19 cases. Questionnaires were administered at the facility level and to  
119 individuals seeking COVID-19 testing services for cost data. For effectiveness measure, we relied on  
120 endpoint data on project-specific reporting forms that included COVID-19 testing registries, laboratory  
121 report forms, patient history, case management forms, contact history forms, competency assessments,  
122 and Ag-RDT ease of use assessments.

123

## 124 Model Structure

125 Figure 1. and 2. depicts the intervention strategies applied. We applied three strategies for the study  
126 scenarios. The first strategy involving the use of Ag-RDT followed by a different diagnosis pathway. Under  
127 the first scenario Ag-RDT was used as the first-line diagnosis method, followed by the prioritization of  
128 negatives for confirmatory testing by NAAT.

129 **Figure 1: Schematic of decision tree mode under scenario 1. +ve, Positive; -ve, Negative; TP: True**  
130 **Positive; FN: False Negative; FP: False Positive; TN: True Negative**

131 **Figure 2: Schematic of decision tree mode under scenario 2. +ve: Positive; -ve: Negative; TP: True**  
132 **Positive; FP: False Positive; FN: False Negative; TN: True Negative**

133 The second scenario involved clinical judgement as the comparator. The first strategy pathway of Ag-RDT  
134 diagnosis and case management did not include a confirmatory test of negatives making the diagnosis  
135 pathway shorter than in the first scenario where there is access to NAAT services.

## 136 Costing Methods

137 The costing followed the Global Health Cost Consortium's (GHCC) reference guidelines [10] to evaluate  
138 the cost of implementing SD Biosensor antigen detecting SARS-Cov-2 diagnostic tests in Kenya. We applied  
139 an ingredient-based approach from a societal perspective to analyze costs for the diagnosing COVID-19  
140 cases using antigen RDT. Under the healthcare system, we costed both the direct and ancillary costs,  
141 which included physical costs and overheads, costs for personal protective equipment (PPE), staff time,  
142 and costs for non-pharmaceuticals. We also computed the direct and indirect costs from the patient  
143 perspective. For the direct cost, we included the cost of testing, the cost for treatment, the cost incurred  
144 for related healthcare services, and the cost of isolation/quarantine. As for the indirect costs, we  
145 considered the travel cost; we valued time spent away from normal activities to visit the healthcare  
146 facilities; we valued informal care, and using the human capital approach, we valued productivity loss due  
147 to absenteeism (figure 3).

148 **Figure 3. Antigen rapid diagnostic test cost component**

149 The costs for treatment, quarantine, and isolation, such as accommodation and overheads,  
150 pharmaceutical, non-pharmaceuticals, staff, PPE, ICU equipment, oxygen therapy, other laboratory tests  
151 associated with COVID-19 case management in hospitals, and cost for diagnostic of patients using PCR  
152 were derived from a previous study [11].

## 153 Physical cost and overheads

154 We obtained outpatient cost overheads from the study on case management of COVID patients [11],  
155 which collected primary data from three public health facilities. We computed the physical cost incurred  
156 per test by collecting data on the estimated cost of the COVID test room, the size of the facility, and the  
157 size of the space the COVID test was being conducted. We later annuitized the estimated cost using the  
158 respective useful life years of the housing facility. To estimate the cost of the testing space after  
159 annuitizing the cost of the housing facility, we first computed the cost per square metre of the housing  
160 facility by dividing the annuitized cost by the size of the housing facility. Second, we multiplied the specific  
161 space size for COVID testing by the cost per square metre of the area housing the test. Finally, we divided  
162 the cost of the COVID space by the number of tests per day and the number of working days in a year,  
163 assuming the daily average test conducted within the last six months and the facility operating every day.

## 164 Non-pharmaceuticals and Personal Protective Equipment (PPE)

165 Data was collected on the non-pharmaceuticals and PPE items used during the testing of suspected Covid-  
166 19 cases. We obtained cost data for NAAT testing from a recent study by Barasa et.al. (2021) on Examining  
167 unit costs for COVID-19 case management in Kenya. The other cost of items for Ag-RDT and quantity  
168 required per test were obtained from the sampled health facilities.

## 169 Staff cost

170 Data was collected on the type of staff, gross salaries, and time spent on testing from three public health  
171 facilities. We computed the amount of time allocated on a test as follows. First, we estimated the total  
172 time allocated to testing in a day by obtaining the number of shifts in a day, the number of the specific  
173 cadre of staff conducting the test, and the length of each shift in minutes. Second, we estimated the  
174 amount of time allocated to a test per day by dividing the number of tests per day, assuming a daily  
175 average of tests conducted within the last six months and equal allocation of testing time. Finally, we  
176 computed the average staff cost per test by multiplying the staff time allocated to COVID-19 testing in a  
177 day in minutes by the gross salary of that cadre of staff per minute.

## 178 Valuing Time cost

179 The time patients lost from routine activities was estimated by adding the travel time and the time spent  
180 at the health facility as per the patient's and companion's response. Using data from Kenya's minimum  
181 wages [12], the time lost was subsequently valued at the average hourly pay of the different categories  
182 of paid work the patient and companion would have engaged. While for the unpaid work, a proxy value  
183 of the cost of a close market substitute was used.

## 184 Valuing Productivity Loss

185 The study considered productivity loss from both paid and replaced unpaid work. Using the human capital  
186 approach, the number of hours worked per working day was calculated based on the average number of  
187 hours a week the patient worked over the last four weeks, assuming the patient worked for five days in a  
188 week. Subsequently, the gross daily wage was estimated by multiplying working hours per day by  
189 estimated hourly salaries for different categories of work [12]. Next, the total number of lost productive  
190 days from paid work was multiplied by the gross daily wage.

191 The cost of replacing unpaid work was considered by analyzing the time spent by an informal giver to  
192 replace the patient missed unpaid work.

## 193 Pricing and Valuation

194 We identified the cost of building as the only capital good, and annuitized it, assuming a useful life of 5  
195 years. We obtained price data from a previous study [11] and presented the costs in Kenya shillings (KES)  
196 and US dollars. We used an exchange rate of US\$1 = KES 112.52 derived from Xe.com and accessed on  
197 30<sup>th</sup> November 2021, to convert KES to US\$. We obtained shadow prices for unpaid work and the  
198 opportunity cost of time from Kenya minimum wages reported by the africanpay.org database accessed  
199 on 30<sup>th</sup> December 2021.

## 200 Effectiveness and Cost-effectiveness measurement

201 The impact of case management of COVID-19 was dependent on the diagnostic performance of the  
202 different diagnostic tests used (Ag-RDT or NAAT), the timing of the test, and the adherence to COVID-19  
203 case management guidelines.

204 The intermediate outcome was measured in terms of the diagnostic performance of the antigen RDT,  
205 which was measured by its sensitivity and specificity compared to the PCR test. Based on the results of  
206 506 test samples, the estimated sensitivity of Ag-RDT is 73%, and the estimated specificity is 93%. Using  
207 the diagnostic test confidence interval formula [13], we obtained a 95% confidence interval for the Ag-  
208 RDT sensitivity as (59%,87%), and the confidence interval for the specificity as (91%,96%).

209 The primary health outcome was measured in terms of the cost per disability-adjusted life years (DALYs)  
210 averted. We factored in both the mortality and morbidity to obtain DALYs by summing up years of life lost  
211 (YLL) and years of life with disability (YLD) [14]. A discounting rate of 3% was used to calculate DALYs and  
212 applied Kenya's life expectancy of 66.34 [15], disability weights as reported [16] and captured in Table.



213 The incremental cost-effectiveness ratio (ICER) comparing the use of Ag-RDT and confirmatory testing of  
214 negatives by NAAT and the use of NAAT as the only diagnostic test conducted was calculated as the  
215 difference in costs and DALYs averted of diagnostic and case management in the compared groups.

$$216 \quad ICER = \frac{(C_{ST1} - C_{ST2})}{(DALY_{S_{ST1}} - DALY_{S_{ST2}})}$$

217 Where ICER = Incremental cost effectiveness ratio; ST1 = RDT as first-line diagnosis followed by NAAT, ST2  
218 = NAAT diagnosis,  $C_{ST1}$  = Cost of strategy 1;  $C_{ST2}$  = Cost of strategy 2;  $DALY_{S_{ST1}}$  = DALYs averted in strategy  
219 1; and  $DALY_{S_{ST2}}$  = DALYs averted in strategy 2.

220 We compared the ICER with an opportunity cost of USD 20.07 to USD 1023.47 (1% to 51% GDP per capita)  
221 based on Kenya's cost-effectiveness threshold as estimated by Woods *et al.* [17] and Ochalek *et al.* [18].

## 222 Assumptions and Parameters

223 Table 1. present the model parameters. The model also used some assumptions that are key to note. First,  
224 we assumed that patients who test positive and show no clinical symptoms of COVID-19 are given home-  
225 based standard care, equivalent to isolation and routine care given to mild COVID-19 patients. Second,  
226 we assume that false-negative and late diagnosis leads to worsening of symptoms [19]. Third, we relied  
227 on a COVID-19 study on an outpatient setting [20] to analyze the outcomes of COVID-19 untreated  
228 patients. Lastly, we assumed that all patients who test positive and no further confirmatory diagnostic  
229 tests conducted are isolated and provided standard care even though the results could be false positive.

230

231 **Table 1: Key model parameters**

Description	Value (Lb;Ub)	Source
<b>Population</b>		
Study cohort population	4918	Author
COVID-19 Prevalence	10%	Author
<b>Cost</b>		
Cost (USD) for asymptomatic care episode	16.39	[11]
Cost (USD) for conducting a PCR test	21.84 (21.60;22.87)	[11]
Cost (USD) for critical care episode	472.02	[11]
Cost (USD) for severe care episode	121.88	[11]
Cost (USD) for conducting a rapid diagnostic test	4.68 (4.83;7.25)	Author
Cost (USD) for clinical diagnosis	5.22 (5.06;5.36)	Author
<b>DALYs</b>		
<b>Disability weight for mild COVID-19</b>	<b>0.006</b>	[16]
Disability weight for critical COVID-19	0.655	[21]
Disability weight for severe COVID-19	0.133	[16]
Average age at death	55.5	[22]
Life expectancy	66.99	[15]
<b>Characteristics of Patients</b>		
Proportion of critical patients hospitalized	0.14	[23]
Proportion of critical COVID-19 who die	0.892	[24]
Proportion of critical COVID-19 who recover	0.108	[24]
Proportion of infected patients with SARS-CoV-2	0.10	Author
Proportion of patients not given asymptomatic care	0	Author
Proportion not infected with SARS-CoV-2	0.90	Author
Proportion of severe patients hospitalized	0.86	[23]
Proportion of severe COVID-19 who progress to critical	0.424	[25]
Proportion of severe COVID-19 who recovered	0.576	[25]
Proportion of patients given asymptomatic care	1	Author
Proportion of severe COVID-19 untreated patients who progresses to critical	1	Author
Proportion of untreated severe COVID-19 patients who recovered	0	Author
Proportion of untreated critical COVID-19 patients who dies	1	Author
Proportion of untreated critical COVID-19 patients who recovered	0	Author
Length of stay asymptomatic care	12	[26]
Length of stay critical	7 (4;10)	[24]
Length of stay severe	6 (3;9)	[14]
<b>Diagnostic Accuracy</b>		
PCR Specificity	0.998 (0.992;0.999)	[27]
PCR Sensitivity	0.86 (0.547;0.994)	[27]
RDT Specificity	0.93 (0.91;0.96)	Author
RDT Sensitivity	0.73 (0.59;0.87)	Author
Probability of correctly excluding SARS-CoV-2	0.683 (0.60;0.758)	[28]
Clinical Judgement Sensitivity	0.806 (0.729;0.869)	[28]

## 232 Dealing with uncertainty

233 We performed a sensitivity analysis on the following parameters: COVID-19 prevalence level; sensitivity  
234 of RDT and PCR; the proportion of treated and untreated hospitalized cases; and cost of RDT, NAAT, and  
235 treatment of severe and critical cases. We implemented a 20% increase or decrease in the cost of RDT,  
236 NAAT, and cost of treatment. The sensitivity analysis of RDT was based on +/- 5% confidence bounds while  
237 the bounds of PCR and clinical judgement were provided [27], [28].

238 We conducted a probabilistic sensitivity analysis to check for the collective uncertainty on the probability  
239 of cost-effectiveness using second-order Monte Carlo simulation (n = 1000). We used beta distributions  
240 to calculate the probability range of the study parameters and gamma distribution on the cost parameters  
241 [29]. Finally, we presented the ICE scatterplot to illustrate the uncertainty in the cost-effectiveness results.

## 242 Results

243 Table 2. summarizes the key findings from the patient questionnaire administered. As per the results, the  
244 primary mode of transport was public transport, with 13 (72%) of the 18 sampled patients preferring  
245 public transport to get to the health facility, and the second most popular means was walking on foot, 3  
246 (17%). It was also noted that most (89%) of the patients went alone to the health facility, and only 11%  
247 were accompanied. The table also details the patient's usual activities foregone by visiting a health facility.  
248 Most of the patient's main activities would be, attending to paid work at 28% or attending to a business  
249 activity at 28%. Housework activities took 17%, whereas only 6% of patients forego childcare activity.

250 It also shows the treatment cost, travel cost, time lost per hour, and time cost from the foregone activity  
251 the patient would have engaged in during the health facility visit, and the productivity loss. The median  
252 travel cost for a one-way visit for a patient was US\$0.27. The study findings also report that out of the  
253 patients accompanied to the health facility, there was no cost incurred by the patient's companion while  
254 visiting the health facility. Applying the values per hour of paid and unpaid work foregone, the median  
255 time cost per hour of both patient's and companion's usual activities lost was US\$1.57. For the  
256 productivity loss, the median productivity cost of absenteeism from both paid and unpaid work was  
257 US\$1.08.

258

259 **Table 2. Key findings from the patient’s questionnaire**

Patient cost		
Mode of transport (no. (%))	Number	Percentage
Public transport	1	6%
Walk on foot	13	72%
Motorcycle and public transport	1	6%
Taxi	3	17%
Patients accompanied (no. (%))	2	11%
<b>Traveling cost (KES)</b>		
Mean (SD)	43.33	40.58
Median (IQR)	30	(20-70)
<b>Cost of related healthcare services (KES)</b>		
Mean (SD)	163.89	387.22
Median (IQR)	0	(0-100)
<b>Patient’s usual activities</b>		
	Number	Percentage
Housework	3	17%
Childcare	1	6%
Attending school	2	11%
Seeking work	1	6%
Paid work	5	28%
Business activity	5	28%
Other	1	6%
<b>Companion’s usual activities</b>		
Attending school	2	11%
<b>Time cost (KES)</b>		
Mean (SD)	247.18	247.51
Median (IQR)	176.89	(50.26-433.42)
<b>Productivity loss (KES)</b>		
Mean (SD)	1000.95	1469.42
Median (IQR)	121.79	(0-2336.4)

260 Table 3. details the unit cost for rapid diagnostic tests compared to NAAT for a COVID-19 suspected case.  
 261 The results showed the unit cost per test for NAAT and Ag-RDT tests in the healthcare system was  
 262 US\$18.93 and US\$3.12, respectively. There is a considerable cost difference between the two tests, mainly  
 263 because of the laboratory cost incurred when conducting the NAAT test. The table also showed the patient  
 264 cost incurred for a diagnostic test was US\$ 2.92; the major cost driver was the patient time cost.  
 265 Summarizing the results, we found that the societal cost for PCR was higher at US\$21.84 than the Ag-RDT  
 266 cost of US\$4.68.

267

268

269 **Table 3: Unit costs for antigen RDT and PCR test for SARS-COV-2 detection**

Inputs	Ag-RDT Test median cost		NAAT Test (PCR) cost [11]	
	(KES)	US\$	KES	US\$
<b>Healthcare perspective</b>				
Physical cost & overheads per test	0.23	0.00	6.66	0.06
Equipment per test	-	-	2.25	0.02
Personal protective equipment (PPE) cost per test	157.72	1.40	151.76	1.35
Consumables cost per test	31.96	0.28	-	-
Lab supplies	-	-	1959.5	17.41
Staff cost per test	7.57	0.07	8.98	0.09
<b>Healthcare estimated cost</b>	<b>197.49</b>	<b>1.76</b>	<b>2129.15</b>	<b>18.93</b>
<b>Patient perspective</b>				
Patient direct cost	0.00	0.00	0.00	0.00
Patient travel cost	30.00	0.27	30.00	0.27
Patient time cost	176.89	1.57	176.89	1.57
Companion travel cost	0.00	0.00	0.00	0.00
Informal care cost	0.00	0.00	0.00	0.00
Patient productivity loss	121.79	1.08	121.79	1.08
<b>Patient estimated cost</b>	<b>328.68</b>	<b>2.92</b>	<b>328.68</b>	<b>2.92</b>
<b>Societal cost</b>	<b>526.17</b>	<b>4.68</b>	<b>2,457.83</b>	<b>21.85</b>

270 **Antigen-RDT and PCR test results**

271 Out of 506 patients recruited, 72 (14.2%) patients tested positive with antigen RDT, 52 (10.3%) patients  
 272 tested positive with PCR test, 38 (7.5%) were positive for both RDT and PCR test, 34 (6.7%) were positive  
 273 for RDT and negative for PCR, 14 (2.8%) were positive to PCR and negative to RDT, and 468 (92.5%) were  
 274 both negative for RDT and PCR test.

275 **Base case results**

276 The costs, DALYs, and the ICER at 10% COVID-19 prevalence level associated with the three strategies are  
 277 presented in Table 4. Under the first scenario, where we apply Ag-RDT as the first-line test and  
 278 prioritization of negatives for the confirmatory test by NAAT in comparison to delaying and conducting  
 279 NAAT, the findings show no-test strategy is dominated. The results show that the RDT strategy is the  
 280 costliest, followed by the no-test strategy, and NAAT test strategy was relatively less costly compared to  
 281 the other two strategies. Although the RDT strategy was costly, it is most effective in averting DALYs to  
 282 NAAT diagnostic strategy, while failure to conduct a test was less effective to Ag-RDT or NAAT. The results  
 283 also showed the ICER of Ag-RDT strategy compared to NAAT diagnostic strategy was US\$964.63 per DALYs

284 averted, hence a cost-effective strategy when we apply Kenya’s maximum cost-effectiveness threshold of  
 285 US\$1003.4. When we compare the three strategy, the results showed no-test strategy was absolutely  
 286 dominated, and it would be more efficient to apply the Ag-RDT strategy to case scenarios where there  
 287 were delay NAAT testing than switching to the no-testing strategy.

288 **Table 4: Cost-effectiveness results for Ag-RDT implementation (USD 2021)**

<b>Scenario 1: Point of care with delayed access to NAAT</b>						
<b>Strategy</b>	<b>Cost (USD)</b>	<b>Incremental Cost (USD)</b>	<b>Effectiveness (DALYs)</b>	<b>Incremental Effectiveness (DALYs)</b>	<b>Incremental cost per DALY averted</b>	<b>Dominance</b>
Delayed test-NAAT	1 107 117.83 (1 102 586.64 to 1 110 014.44)		2236.49 (2229.01 to 2239.81)			undominated
No test, Clinical Judgement	1 261 230.4 (1 258 276.99 to 1 264 097.03)	154 112.57	2361.35 (2360.40 to 2362.44)	-124.86	-1234.26	abs. dominated
Ag-RDT	1 336 231.13 (1 332 224.48 to 1 339 721.30)	229 113.3	1998.97 (1996.95 to 1999.87)	237.51	964.63	undominated
<b>Scenario 2: Point of care with no access to NAAT</b>						
<b>Strategy</b>	<b>Cost (USD)</b>	<b>Incremental Cost (USD)</b>	<b>Effectiveness (DALYs)</b>	<b>Incremental Effectiveness (DALYs)</b>	<b>Incremental cost per DALY averted</b>	<b>Dominance</b>
Ag-RDT	998 260.67 (970 948.12 to 1 011 265.58)		2537.8 (2330.70 to 2638.70)			undominated
No test, Clinical judgement	1 261 230.78 (1 258 276.99 to 1 264 097.03)	2 62 970.12	2361.35 (2330.70 to 2638.70)	176.45	1490.34	undominated

289 Under the second scenario, where Ag-RDT is the only feasible tool to aid testing, the no-test strategy is  
 290 costly compared to Ag-RDT diagnostic strategy. As for effectiveness, the results show no-test strategy is  
 291 more effective in averting DALYs than the RDT strategy but with an ICER of US\$1490.34 no-test strategy  
 292 was not cost-effective in Kenya.

## 293 Sensitivity Analysis

### 294 Difference prevalence level from 5% to 20%

295 A one-way sensitivity analysis showed the ICER was sensitive to the covid-19 prevalence level. The results  
 296 (S1 Table) showed that at less than 5% covid-19 prevalence level and under a case where there was access  
 297 to delayed NAAT, the use of RDT and further confirmatory by NAAT strategy was not cost-effective

298 compared to the delayed NAAT strategy. At a prevalence rate of more than 5% to 20%, the results showed  
299 that the use of RDT and further confirmatory of negatives by NAAT was cost-effective compared to the  
300 delayed NAAT strategy.

301 In a scenario with no access to NAAT assay, at a lower prevalence rate of 5% to 16.25%, no-test strategy  
302 was still not cost-effective compared to the RDT strategy (S2 Table). The results showed at a higher  
303 prevalence rate of 20%, the no-test strategy was more costly and more effective than the Ag-RDT strategy,  
304 and the ICER was US\$989.15 hence a cost-effective strategy.

### 305 RDT and PCR Sensitivity

306 When we varied the sensitivity of RDT (S3 Table) by increasing or reducing RDT sensitivity, we found  
307 applying RDT as the first-line tool to aid in testing, followed by prioritization of negatives for confirmatory  
308 testing by NAAT was still costly and more effective up to a sensitivity level  $\geq 87\%$  to delayed NAAT  
309 diagnostic strategy.

310 In a scenario where there was no access to NAAT assay, RDT was still less costly and less effective than  
311 the no-test strategy (S4 Table) and in the two scenarios we found the ICER was sensitive to changes in  
312 RDT sensitivity.

313 When we varied the PCR sensitivity by increasing it, we found PCR was less costly and less effective than  
314 RDT. While reducing the PCR sensitivity also led to reduction in the costs of PCR diagnostic strategy and  
315 was attractively effective under the three strategies (S5 Table).

316 According to Figure 4. the key parameters that had the most significant effect on the ICER when we  
317 compared the RDT diagnostic strategy to the delayed NAAT diagnostic strategy are 1) Proportion of severe  
318 patients hospitalized 2) Proportion of critical patients hospitalized (both of which fewer cases improves  
319 cost-effectiveness); 3) Probability of critical patient dying (lower mortality for critical patients improves  
320 cost-effectiveness); 4) Length of stay for critical patients (shorter length of stay in the hospital improves  
321 cost-effectiveness).

322 **Figure 4: Tornado diagram of one-way sensitivity analysis of the parameters affecting the ICER under**  
323 **scenario 1. YLL, years of life lost; YLD, years of life lived with disability; RDT, rapid diagnostic test; DALYs,**  
324 **disease life adjusted years**

325 Comparing RDT diagnostic strategy and no-test strategy, Figure 5. summarizes the three parameters that  
326 had the most significant effect on the ICER. These are: 1) Clinical true positive; (reduction in true positive

327 cases improves cost-effectiveness); 2) Clinical false positive (reduction in false-positive diagnosed cases  
328 improves cost-effectiveness, and 3) Proportion of infected SARS-Cov-2 (reduction in SARS-CoV-2 infection  
329 improves cost-effectiveness).

330 **Figure 5: Tornado diagram of one-way sensitivity analysis of the parameters affecting the ICER under**  
331 **scenario 2. YLL, years of life lost; YLD, years of life lived with disability; PCR, polymerase chain reaction;**  
332 **RDT, rapid diagnostic test; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2**

### 333 Probabilistic Sensitivity Analysis

334 The results of the Monte Carlo simulation of 1000 samples under the first scenario (Figure 6.) show that  
335 at a cost-effectiveness threshold of US\$ 1003.4 per DALYs averted, the probability of antigen rapid  
336 diagnostic test being the more cost-effective strategy was 52.5%. Under the second scenario, the results  
337 for PSA (Figure 7.) show that at a cost-effectiveness threshold of US\$ 1003.4 per DALYs averted, the  
338 probability of the no-test diagnostic strategy being more cost-effective was 28.7%.

339 **Figure 6: Probabilistic sensitivity analysis of Ag-RDT diagnostic strategy versus delayed nucleic acid**  
340 **amplifying test diagnostic strategy under scenario 1. Green dots representing the points that are cost-**  
341 **effective (below the willingness to pay (WTP)). While the red dots represent the points that are not**  
342 **cost-effective (above the WTP)**

343 **Figure 7: Probabilistic sensitivity analysis of Ag-RDT diagnostic strategy versus delayed nucleic acid**  
344 **amplifying test diagnostic strategy under scenario 1. Green dots representing the points that are cost-**  
345 **effective (below the willingness to pay (WTP)). While the red dots represent the points that are not**  
346 **cost-effective (above the WTP)**

347 Figures 8 and 9 present cost-effectiveness acceptability curves under scenario one and scenario, two  
348 respectively based on a range of cost-effectiveness thresholds. Under a scenario where there is delayed  
349 NAAT diagnosis and given a willingness to pay of US\$ 900 per DALYs averted, there was a 40% probability  
350 of the Ag-RDT strategy being cost-effective. The cost-effectiveness acceptability curve shows the  
351 probability of the AG-RDT strategy being more cost-effective as the decision maker was willing to increase  
352 their willingness to pay (Figure 8). Under a scenario where there is no access to NAAT assay in a resource-  
353 limited setting and a decision maker is not willing to pay for any DALYs averted, the probability of Ag-RDT  
354 being cost-effective compared to no-test strategy was 94%.



355 **Figure 8: Cost-effectiveness acceptability curve showing the probability of cost-effectiveness of Ag-RDT**  
356 **strategy compared to Delayed test NAAT strategy and No-test Strategy over a range of willingness-to-**  
357 **pay values.**

358 **Figure 9: Cost-effectiveness acceptability curve showing the probability of cost-effectiveness of Ag-RDT**  
359 **strategy compared to No-test Strategy over a range of willingness-to-pay values.**

## 360 Discussion

361 The study presents the cost and cost-effectiveness of Ag-RDTs over PCR and clinical judgement for SARS-  
362 CoV-2 detection. We compared the use of Ag-RDT under three scenarios using three diagnostic strategies.  
363 Our findings show that when we compare the first strategy of using Ag-RDT as the first-line tool and later  
364 conducting confirmatory tests of negatives to the second strategy of delaying the testing and using the  
365 services of NAAT assays. Ag-RDT diagnostic strategy is costly compared to delayed NAAT diagnostic  
366 strategy, the high cost being driven by increased detection of true positives on a confirmatory test of RDT  
367 negatives results using PCR test hence increase in the cost of case management of diagnosed positive  
368 cases. We also find that using RDT and subjecting the negative RDT results to confirmatory PCR test  
369 averted more DALYs on infected SARS-CoV-2 patients not detected by RDT. When we compare the two  
370 strategies at  $\geq 8.75\%$  Covid-19 prevalence level, we find that using Ag-RDT as a first-line tool and later  
371 conducting confirmatory tests of negatives was a cost-effective strategy.

372 When we compared the use of Ag-RDT as the only feasible tool to aid in detecting SARS-CoV-2 to the use  
373 of clinical judgement, at  $\leq 16.25\%$  Covid-19 prevalence level, the results show no-test strategy was not  
374 cost-effective compared to the use of Ag-RDT strategy. The results of the two strategies show that Ag-  
375 RDT is less costly and less effective than the clinical strategy, which is substantially more costly and more  
376 effective. We can explain the high-cost findings associated with clinical diagnostic strategy to treat  
377 presumptive cases with clinical symptoms similar to SARS-CoV-2 infected patients. The clinical diagnostic  
378 strategy averts more DALYs than the RDT strategy since most cases with SARS CoV-2 clinical symptoms  
379 are subjected to care/treatment. Still, in a resource-limited setting, in the case of Kenya, the strategy may  
380 not be cost-effective due to the high cost associated with the strategy. At a higher prevalence level, a  
381 presumptive diagnosis of SARS-CoV-2 has been found to have a higher sensitivity level and a relatively  
382 lower specificity level [30]. The results show at a higher Covid-19 prevalence level (20% prevalence), the  
383 use of a no-test, clinical judgement strategy was cost-effective in averting DALYs compared to the use of  
384 Ag-RDT strategy at a relatively high willingness to pay threshold.

385 Our findings show the proportion of severe and critical cases hospitalized impacts more on the cost-  
386 effectiveness of the Ag-RDT strategy. This could be explained by the fact that a low (high) proportion of  
387 severe and critical cases hospitalized implies a low (high) Covid-19 prevalence level, which in turn provides  
388 a reason for an accurate diagnosis to avert more DALYs and cost implications associated with  
389 misdiagnosis. When we consider delayed NAAT strategy previous studies have shown late diagnosis may  
390 not be associated with ICU admission or death [19] hence delay in obtaining results or access to NAAT  
391 cannot be linked to the patient disease progression and recovery. Although, it can be argued that late  
392 diagnosis of COVID-19 patients can increase the risk of infection, especially contact with individuals such  
393 as caregivers, as personal protective equipment may not be used. When considerations are made to  
394 implement RDT diagnostic strategy in settings with delayed access to NAAT, it will avert more DALYs than  
395 delay NAAT diagnostic strategy.

396 The major limitation of this study is the scarce data on the outcomes of COVID-19 patients with false-  
397 negative diagnosis results. However, we made assumptions based on disease progression and outcome  
398 during the peak of the COVID-19 pandemic for the COVID-19 cases that were not given any care. One  
399 strength of this analysis is the fact that it considered the diagnostic cost and the treatment cost associated  
400 with false-positive cases. This paper is among the first papers on cost effectiveness of Ag RDTs in low- and  
401 middle-income countries.

## 402 Conclusion

403 The study findings should inform policymakers to support the implementation of the Ag-RDT diagnostic  
404 strategy in a scenario where there is delayed access to confirmatory NAAT testing. At a high prevalence  
405 level, the use of Ag-RDT diagnostic kits would be a cost-effective strategy compared to delaying and  
406 applying the NAAT testing strategy. Under a scenario where there is no access to NAAT assay, the optimal  
407 strategy would be to support the use of RDT rather than resorting to clinical judgement as a strategy for  
408 diagnosis. Since the use of Ag-RDT would be a cost-saving strategy and an optimal strategy in a resource-  
409 limited setting like Kenya. There is an increased opportunity for cost-effectiveness and cost savings if Ag-  
410 RDT is introduced to complement the use of NAAT assay where there are delays in confirmatory testing  
411 and scenarios where there is no access to NAAT assay. The implementation and roll-out of Ag-RDT will  
412 reduce the risk of misdiagnosis and case management of false positive cases, especially in a rural setting  
413 where due to lack of NAAT assay there may be an overreliance on clinical judgement to diagnose Covid-  
414 19 suspected cases.

## 415 Ethical considerations

416 This research was approved by the Ethics committee of Kenya Methodist University and all participants  
417 signed a written consent form to participate to the study

## 418 Policy implication

419 This paper will give important insight on cost effective tests to use in a pandemic and will help decision  
420 makers to use efficiently the scarce healthcare resources

## 421 Funding

422 The project that generated data used in this study was made possible by the generous support of the  
423 World Health Organization. The study was an implementation Research on the use of Antigen Rapid  
424 Diagnostic Tests for Coronavirus Disease 2019 (COVID-19). The study entailed the assessment of field  
425 performance, feasibility, acceptability, ease of use and impact of Ag-RDTs for the diagnosis of SARS-CoV-  
426 2 infection in Kenya. The funding was awarded to JG. The funders had no role in study design, data  
427 collection and analysis, decision to publish, or preparation of the manuscript.

## 428 Acknowledgement

429 We are grateful to the Mount Kenya University study team fieldworkers who collected effectiveness data.

430

## 431 References

- 432 [1] C. K. C. Lai and W. Lam, "Laboratory testing for the diagnosis of COVID-19," *Biochem. Biophys. Res.*  
433 *Commun.*, vol. 538, pp. 226–230, Jan. 2021, doi: 10.1016/j.bbrc.2020.10.069.
- 434 [2] "WHO Emergency Use Listing for In vitro diagnostics (IVDs) Detecting SARS-CoV-2."  
435 <https://www.who.int/publications/m/item/200922-eul-sars-cov2-product-list> (accessed Mar. 17,  
436 2022).
- 437 [3] J. Jacobs, V. Kühne, O. Lunguya, D. Affolabi, L. Hardy, and O. Vandenberg, "Implementing COVID-19  
438 (SARS-CoV-2) Rapid Diagnostic Tests in Sub-Saharan Africa: A Review," *Front. Med.*, vol. 7, p.  
439 557797, 2020, doi: 10.3389/fmed.2020.557797.
- 440 [4] S. Ricks, E. A. Kendall, D. W. Dowdy, J. A. Sacks, S. G. Schumacher, and N. Arinaminpathy,  
441 "Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a  
442 modelling analysis," *BMC Med.*, vol. 19, no. 1, p. 75, Mar. 2021, doi: 10.1186/s12916-021-01948-z.
- 443 [5] S. Prinja, A. Nandi, S. Horton, C. Levin, and R. Laxminarayan, "Costs, Effectiveness, and Cost-  
444 Effectiveness of Selected Surgical Procedures and Platforms," in *Essential Surgery: Disease Control*  
445 *Priorities, Third Edition (Volume 1)*, H. T. Debas, P. Donkor, A. Gawande, D. T. Jamison, M. E. Kruk,  
446 and C. N. Mock, Eds. Washington (DC): The International Bank for Reconstruction and  
447 Development / The World Bank, 2015. Accessed: Oct. 25, 2022. [Online]. Available:  
448 <http://www.ncbi.nlm.nih.gov/books/NBK333516/>
- 449 [6] World Health Organization, "Antigen-detection in the diagnosis of SARS-CoV-2 infection using  
450 rapid immunoassays: interim guidance, 11 September 2020," World Health Organization,  
451 WHO/2019-nCoV/Antigen\_Detection/2020.1, 2020. Accessed: Mar. 17, 2022. [Online]. Available:  
452 <https://apps.who.int/iris/handle/10665/334253>
- 453 [7] M. of Health, Kenya, "INTERIM GUIDELINES ON MANAGEMENT OF COVID-19 IN KENYA."  
454 <http://publications.universalhealth2030.org/ref/408595280af95072fe155e1fee40a7f4> (accessed  
455 Mar. 17, 2022).
- 456 [8] "WHO COVID-19 Case definition." [https://www.who.int/publications-detail-redirect/WHO-2019-](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2)  
457 [nCoV-Surveillance\\_Case\\_Definition-2020.2](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2) (accessed Mar. 17, 2022).
- 458 [9] N. M. Buderer, "Statistical methodology: I. Incorporating the prevalence of disease into the sample  
459 size calculation for sensitivity and specificity," *Acad. Emerg. Med. Off. J. Soc. Acad. Emerg. Med.*,  
460 vol. 3, no. 9, pp. 895–900, Sep. 1996, doi: 10.1111/j.1553-2712.1996.tb03538.x.
- 461 [10] A. Vassall *et al.*, "Reference Case for Estimating the Costs of Global Health Services and  
462 Interventions," p. 91.
- 463 [11] E. Barasa *et al.*, "Examining unit costs for COVID-19 case management in Kenya," *BMJ Glob. Health*,  
464 vol. 6, no. 4, p. e004159, Apr. 2021, doi: 10.1136/bmjgh-2020-004159.
- 465 [12] "Minimum Wages," *WageIndicator subsite collection*.  
466 <https://africapay.org/kenya/salary/minimum-wages/2182-cities-nairobi-mombasa-and-kisumu>  
467 (accessed Apr. 05, 2022).
- 468 [13] A. S. Hess *et al.*, "Methods and recommendations for evaluating and reporting a new diagnostic  
469 test," *Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol.*, vol. 31, no. 9, pp. 2111–  
470 2116, Sep. 2012, doi: 10.1007/s10096-012-1602-1.
- 471 [14] A. Kairu, V. Were, L. Isaaka, A. Agweyu, S. Aketch, and E. Barasa, "Modelling the cost-effectiveness  
472 of essential and advanced critical care for COVID-19 patients in Kenya," *BMJ Glob. Health*, vol. 6,  
473 no. 12, p. e007168, Dec. 2021, doi: 10.1136/bmjgh-2021-007168.
- 474 [15] "Life expectancy at birth, total (years) - Kenya | Data."  
475 <https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=KE> (accessed Mar. 17, 2022).
- 476 [16] J. A. Salomon *et al.*, "Disability weights for the Global Burden of Disease 2013 study," *Lancet Glob.*  
477 *Health*, vol. 3, no. 11, pp. e712–723, Nov. 2015, doi: 10.1016/S2214-109X(15)00069-8.

- 478 [17] B. Woods, P. Revill, M. Sculpher, and K. Claxton, "Country-Level Cost-Effectiveness Thresholds:  
479 Initial Estimates and the Need for Further Research," *Value Health*, vol. 19, no. 8, pp. 929–935,  
480 Dec. 2016, doi: 10.1016/j.jval.2016.02.017.
- 481 [18] J. Ochalek, J. Lomas, and K. Claxton, "Estimating health opportunity costs in low-income and  
482 middle-income countries: a novel approach and evidence from cross-country data," *BMJ Glob.  
483 Health*, vol. 3, no. 6, p. e000964, Nov. 2018, doi: 10.1136/bmjgh-2018-000964.
- 484 [19] E. R. Pfoh, E. H. Hariri, A. D. Misra-Hebert, A. Deshpande, L. Jehi, and M. B. Rothberg, "Late  
485 Diagnosis of COVID-19 in Patients Admitted to the Hospital," *J. Gen. Intern. Med.*, vol. 35, no. 9, pp.  
486 2829–2831, Sep. 2020, doi: 10.1007/s11606-020-05949-1.
- 487 [20] R. Derwand, M. Scholz, and V. Zelenko, "COVID-19 outpatients: early risk-stratified treatment with  
488 zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study," *Int. J.  
489 Antimicrob. Agents*, vol. 56, no. 6, p. 106214, Dec. 2020, doi: 10.1016/j.ijantimicag.2020.106214.
- 490 [21] J. A. Haagsma *et al.*, "Assessing disability weights based on the responses of 30,660 people from  
491 four European countries," *Popul. Health Metr.*, vol. 13, p. 10, Apr. 2015, doi: 10.1186/s12963-015-  
492 0042-4.
- 493 [22] L. A. Ombajo *et al.*, "Epidemiological and Clinical Characteristics of Covid-19 Patients in Kenya."  
494 medRxiv, p. 2020.11.09.20228106, Nov. 12, 2020. doi: 10.1101/2020.11.09.20228106.
- 495 [23] J. B. Nachega *et al.*, "Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in  
496 Africa: Early Insights from the Democratic Republic of the Congo," *Am. J. Trop. Med. Hyg.*, vol. 103,  
497 no. 6, pp. 2419–2428, Dec. 2020, doi: 10.4269/ajtmh.20-1240.
- 498 [24] D. Liu *et al.*, "Risk factors for developing into critical COVID-19 patients in Wuhan, China: A  
499 multicenter, retrospective, cohort study," *EClinicalMedicine*, vol. 25, p. 100471, Aug. 2020, doi:  
500 10.1016/j.eclinm.2020.100471.
- 501 [25] M. Elhadi *et al.*, "Epidemiology, outcomes, and utilization of intensive care unit resources for  
502 critically ill COVID-19 patients in Libya: A prospective multi-center cohort study," *PLOS ONE*, vol.  
503 16, no. 4, p. e0251085, Apr. 2021, doi: 10.1371/journal.pone.0251085.
- 504 [26] W. Guan *et al.*, "Clinical Characteristics of Coronavirus Disease 2019 in China," *N. Engl. J. Med.*, vol.  
505 382, no. 18, pp. 1708–1720, Apr. 2020, doi: 10.1056/NEJMoa2002032.
- 506 [27] T. A. Perkins, M. Stephens, W. Alvarez Barrios, S. Cavany, L. Rulli, and M. E. Pfrender, "Performance  
507 of Three Tests for SARS-CoV-2 on a University Campus Estimated Jointly with Bayesian Latent Class  
508 Modeling," *Microbiol. Spectr.*, vol. 10, no. 1, pp. e01220–21, doi: 10.1128/spectrum.01220-21.
- 509 [28] R. Diel and A. Nienhaus, "Point-of-care COVID-19 antigen testing in German emergency rooms – a  
510 cost-benefit analysis," *Pulmonology*, Jul. 2021, doi: 10.1016/j.pulmoe.2021.06.009.
- 511 [29] A. H. Briggs *et al.*, "Model parameter estimation and uncertainty analysis: a report of the ISPOR-  
512 SMDM Modeling Good Research Practices Task Force Working Group-6," *Med. Decis. Mak. Int. J.  
513 Soc. Med. Decis. Mak.*, vol. 32, no. 5, pp. 722–732, Oct. 2012, doi: 10.1177/0272989X12458348.
- 514 [30] C. A. Romero-Gameros *et al.*, "Diagnostic accuracy of symptoms as a diagnostic tool for SARS-CoV  
515 2 infection: a cross-sectional study in a cohort of 2,173 patients," *BMC Infect. Dis.*, vol. 21, no. 1, p.  
516 255, Mar. 2021, doi: 10.1186/s12879-021-05930-1.
- 517

518

## 519 Supporting information

520 **S1 Table:** Different prevalence levels from 5% to 20% sensitivity report scenario 1

521 **S2 Table:** Different prevalence levels from 5% to 20% sensitivity report scenario 2


522 **S3 Table:** RDT Sensitivity Report Scenario 1

523 **S4 Table:** RDT Sensitivity Report Scenario 2

524 **S5 Table:** PCR Sensitivity Report


525

Figure 1.



medRxiv preprint doi: <https://doi.org/10.1101/2023.01.05.23284225>; this version posted January 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).


Figure 2.



medRxiv preprint doi: <https://doi.org/10.1101/2023.01.05.23284225>; this version posted January 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.




Figure 3.




medRxiv preprint doi: <https://doi.org/10.1101/2023.01.05.23284225>; this version posted January 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 4.




medRxiv preprint doi: <https://doi.org/10.1101/2023.01.05.23284225>; this version posted January 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 5.



medRxiv preprint doi: <https://doi.org/10.1101/2023.01.05.23284225>; this version posted January 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 6.



medRxiv preprint doi: <https://doi.org/10.1101/2023.01.05.23284225>; this version posted January 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 7.






Figure 8.



medRxiv preprint doi: <https://doi.org/10.1101/2023.01.05.23284225>; this version posted January 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 9.



medRxiv preprint doi: <https://doi.org/10.1101/2023.01.05.23284225>; this version posted January 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).